These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 26098203)

  • 21. Personalized Medicine in Gastrointestinal Stromal Tumor (GIST): Clinical Implications of the Somatic and Germline DNA Analysis.
    Ravegnini G; Nannini M; Sammarini G; Astolfi A; Biasco G; Pantaleo MA; Hrelia P; Angelini S
    Int J Mol Sci; 2015 Jul; 16(7):15592-608. PubMed ID: 26184165
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.
    Prenen H; Cools J; Mentens N; Folens C; Sciot R; Schöffski P; Van Oosterom A; Marynen P; Debiec-Rychter M
    Clin Cancer Res; 2006 Apr; 12(8):2622-7. PubMed ID: 16638875
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Evidence-based treatment of gastrointestinal stromal tumor (GIST) with tyrosine kinase inhibitors-imatinib and sunitinib].
    Nishida T; Omori T; Ueshima S
    Gan To Kagaku Ryoho; 2011 May; 38(5):733-7. PubMed ID: 21566432
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A safety evaluation of imatinib mesylate in the treatment of gastrointestinal stromal tumor.
    Ben Ami E; Demetri GD
    Expert Opin Drug Saf; 2016; 15(4):571-8. PubMed ID: 26865352
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group.
    Patrikidou A; Domont J; Chabaud S; Ray-Coquard I; Coindre JM; Bui-Nguyen B; Adenis A; Rios M; Bertucci F; Duffaud F; Chevreau C; Cupissol D; Pérol D; Emile JF; Blay JY; Le Cesne A;
    Eur J Cancer; 2016 Jan; 52():173-80. PubMed ID: 26687836
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nursing implications of imatinib as molecularly targeted therapy for gastrointestinal stromal tumors.
    Griffin JM; Amand MS; Demetri GD
    Clin J Oncol Nurs; 2005 Apr; 9(2):161-9. PubMed ID: 15853160
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Case of Disseminated Intra-abdominal Gastrointestinal Stromal Tumor Managed with Low Dose Imatinib.
    Jang BH; Kim BW; Lim KJ; Kim BG; Park SM; Kim JS; Ji JS; Choi H
    Korean J Gastroenterol; 2015 Jun; 65(6):366-9. PubMed ID: 26087692
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term efficacy of imatinib for treatment of metastatic GIST.
    Patel S
    Cancer Chemother Pharmacol; 2013 Aug; 72(2):277-86. PubMed ID: 23503753
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Concomitant KIT/BRAF and PDGFRA/BRAF mutations are rare events in gastrointestinal stromal tumors.
    Rossi S; Sbaraglia M; Dell'Orto MC; Gasparotto D; Cacciatore M; Boscato E; Carraro V; Toffolatti L; Gallina G; Niero M; Pilozzi E; Mandolesi A; Sessa F; Sonzogni A; Mancini C; Mazzoleni G; Romeo S; Maestro R; Dei Tos AP
    Oncotarget; 2016 May; 7(21):30109-18. PubMed ID: 27097112
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Novel HSP90 inhibitor, IPI-493, is highly effective in human gastrostrointestinal stromal tumor xenografts carrying heterogeneous KIT mutations.
    Floris G; Sciot R; Wozniak A; Van Looy T; Wellens J; Faa G; Normant E; Debiec-Rychter M; Schöffski P
    Clin Cancer Res; 2011 Sep; 17(17):5604-14. PubMed ID: 21737509
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Advanced or metastatic gastrointestinal stromal tumors: systemic treatment options.
    Caram MV; Schuetze SM
    J Surg Oncol; 2011 Dec; 104(8):888-95. PubMed ID: 22069173
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Medical therapy of GIST; from palliative to curative treatment].
    Le Cesne A; Blay JY
    Bull Acad Natl Med; 2012; 196(4-5):861-74; discussion 874-76. PubMed ID: 23550449
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Opposing roles of KIT and ABL1 in the therapeutic response of gastrointestinal stromal tumor (GIST) cells to imatinib mesylate.
    Rausch JL; Boichuk S; Ali AA; Patil SS; Liu L; Lee DM; Brown MF; Makielski KR; Liu Y; Taguchi T; Kuan SF; Duensing A
    Oncotarget; 2017 Jan; 8(3):4471-4483. PubMed ID: 27965460
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Deciding on the duration of adjuvant therapy in gastrointestinal stromal tumor.
    Whooley P; Correa E; von Mehren M
    Expert Rev Anticancer Ther; 2021 May; 21(5):547-556. PubMed ID: 33353442
    [No Abstract]   [Full Text] [Related]  

  • 35. Knowns and Known Unknowns of Gastrointestinal Stromal Tumor Adjuvant Therapy.
    Martínez-Marín V; Maki RG
    Gastroenterol Clin North Am; 2016 Sep; 45(3):477-86. PubMed ID: 27546844
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Story of Imatinib in GIST - a Journey through the Development of a Targeted Therapy.
    Reichardt P
    Oncol Res Treat; 2018; 41(7-8):472-477. PubMed ID: 29895025
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Unbiased compound screening identifies unexpected drug sensitivities and novel treatment options for gastrointestinal stromal tumors.
    Boichuk S; Lee DJ; Mehalek KR; Makielski KR; Wozniak A; Seneviratne DS; Korzeniewski N; Cuevas R; Parry JA; Brown MF; Zewe J; Taguchi T; Kuan SF; Schöffski P; Debiec-Rychter M; Duensing A
    Cancer Res; 2014 Feb; 74(4):1200-13. PubMed ID: 24385214
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacogenetics of tyrosine kinase inhibitors in gastrointestinal stromal tumor and chronic myeloid leukemia.
    Ravegnini G; Sammarini G; Angelini S; Hrelia P
    Expert Opin Drug Metab Toxicol; 2016 Jul; 12(7):733-42. PubMed ID: 27149004
    [TBL] [Abstract][Full Text] [Related]  

  • 39. microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome.
    Akçakaya P; Caramuta S; Åhlen J; Ghaderi M; Berglund E; Östman A; Bränström R; Larsson C; Lui WO
    Br J Cancer; 2014 Nov; 111(11):2091-102. PubMed ID: 25349971
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutational Testing in Gastrointestinal Stromal Tumor.
    Wang Y; Call J
    Curr Cancer Drug Targets; 2019; 19(9):688-697. PubMed ID: 30914028
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.